Description
Naftopidil is an inhibitor of α1-adrenergic receptors that is clinically used to improve lower urinary tract symptoms in subjects with benign prostatic hyperplasia (BPH). In clinical trials, naftopidil improves nocturnal polyuria. Naftopidil improves bladder capacity through both its effect on adrenergic signaling as well as inhibition of c-fiber afferent nerves. Additionally, this compound inhibits collagen-induced Ca2+ mobilization and platelet aggregation in vitro, exhibiting potential anti-platelet benefit.